Scancell, investment in cancer vaccines

Oxford Capital Partners announces an investment in Scancell.

 

Scancell, a biotechnology company based in Nottingham’s BioCity, is developing products that stimulate the immune system to treat or prevent cancer. The Company has four therapeutic antibodies in development and a pipeline of improved cancer vaccines based upon its proprietary ImmunoBody™ technology.

Scancell spun-out from the University of Nottingham in 1996 and has since become a significant player in the discovery and development of therapeutic antibodies and vaccines for the treatment of cancer.

Oxford Capital Partners’ investment will help the company to move new products through the pipeline.

22 February 2004

For further information, contact David Mott on 01865 860 760 or by email.

Notes to Editors

Oxford Capital Partners is a science investment banking firm with over 10 years of experience of investing and supporting high technology businesses. Based in Oxford, the company specialises in identifying exceptional early stage companies with high growth potential. Oxford Capital Partners is an active supporter of the UK’s science and technology base.

Scancell Ltd is a company focused on the discovery and development of products that harness the immune system in a unique way to treat or prevent cancer. Founded in 1996 as a spin-out from Nottingham University, Scancell in based in state-of-the-art facilities at the BioCity innovation and technology centre, Nottingham. The Company, which currently employs 15 individuals, has secured £3.7million of private equity and commercial funding. Scancell has four monoclonal antibody products in active development and has also developed its patent protected ImmunoBody™ technology for the discovery of improved cancer vaccines. It has already secured three major technology-validating collaborations with significant players in the sector including Celltech, the acknowledged flagship of the UK biotechnology industry, Genmab, a leading Danish antibody company and ISU, a company at the forefront of Korean biotechnology. For more information about Scancell visit www.scancell.co.uk

Share this page: